Vaccines

June, 2022

Abstract

Introduction: In 2020, prior to COVID-19 vaccine rollout, the Coalition for Epidemic Preparedness Innovations and Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We leveraged the Brighton Collaboration list to evaluate serious adverse events of special interest observed in phase III randomized trials of mRNA COVID-19 vaccines.

January, 2022

Highlights

• mRNA vaccines promote sustained synthesis of the SARS-CoV-2 spike protein.

• The spike protein is neurotoxic, and it impairs DNA repair mechanisms.

• Suppression of type I interferon responses results in impaired innate immunity.

• The mRNA vaccines potentially cause increased risk to infectious diseases and cancer.

• Codon optimization results in G-rich mRNA that has unpredictable complex effects.

Abstract

January, 2022

Highlights

• Vaccination confers broader IgG binding of variant RBDs than SARS-CoV-2 infection

• Imprinting from initial antigen exposures alters IgG responses to viral variants

• Histology of mRNA vaccinee lymph nodes shows abundant germinal centers

• Vaccine spike antigen and mRNA persist for weeks in lymph node germinal centers

Abstract

April, 2022

Key Points

Question: Does prior mRNA-1273 vaccination influence anti-nucleocapsid antibody seroconversion and/or seroreversion after SARS-CoV-2 infection?

April, 2022

Abstract

March, 2022

Abstract

February, 2022

Abstract

February, 2022

Abstract

Vaccination policies have shifted dramatically during COVID-19 with the rapid emergence of population-wide vaccine mandates, domestic vaccine passports, and differential restrictions based on vaccination status. These policies have prompted ethical, scientific, practical, and political controversy; however, there has been limited evaluation of their potential unintended consequences. Here, we outline a comprehensive set of hypotheses for why these policies may be counter-productive and harmful.

Our framework considers four domains:

DSA ADS Course - 2022

COVID19, Public Policy, Health Policy, mRNA Vaccines, Vaccines, Clinical Trial Design, Evidence Hierarchy

This is a FOIA document of the first 2.5 months after the vaccine roll-out. Discuss clinical trial design and hierarchy of evidence in context of mRNA vaccines.

5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021